Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PYGM | P11217 | 1/20 | 0.41 |
| ▸ | PLD2 | O14939 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549459 | 0.95 | AR (0.45) | FLT3CYP51A1SMYD3PYGLDRD2 | |
| SCHEMBL1931683 | 0.93 | DRD2 (0.47) | CYP51A1PYGLDRD2STAT6HRH4 | |
| SCHEMBL1931738 | 0.93 | DRD2 (0.47) | CYP51A1PYGLDRD2STAT6HRH4 | |
| SCHEMBL1931303 | 0.93 | DRD2 (0.47) | CYP51A1PYGLDRD2STAT6HRH4 | |
| SCHEMBL1549547 | 0.91 | PDGFRB (0.46) | CYP51A1PYGLDRD2STAT6HRH4 | |
| SCHEMBL1550025 | 0.91 | PYGL (0.48) | CYP51A1SMYD3PYGLDRD2HRH4 | |
| SCHEMBL2640155 | 0.89 | STAT6 (0.43) | CYP51A1PYGLDRD2STAT6HRH4 | |
| SCHEMBL1550291 | 0.89 | CYP51A1 (0.42) | FLT3CYP51A1SMYD3PYGLPLD1 | |
| SCHEMBL1550637 | 0.88 | PDGFRB (0.48) | FLT3PYGLSTAT6HRH4PYGM | |
| SCHEMBL1931701 | 0.88 | HRH4 (0.46) | CYP51A1DRD2STAT6HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925857-B1 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | UNIV INDIANA RES & TECH CORP (US) | 2018-02-14 | — | — | EP | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| JP-2011529082-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | FLT3 3525/4885CYP51A1 2877/4885SMYD3 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.